Allianz Asset Management
ITOS

Allianz Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Allianz Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,542
Closed -$280K – 2193
2024
Q1 		$280K Buy
+20,542
New +$224K ﹤0.01% 1774
2023
Q4 		– Sell
-32,200
Closed -$353K – 2189
2023
Q3 		$353K Sell
32,200
-23,087
-42% -$295K ﹤0.01% 2030
2023
Q2 		$732 Buy
55,287
+25,108
+83% +$358K ﹤0.01% 2059
2023
Q1 		$411K Buy
+30,179
New +$541K ﹤0.01% 1942
2022
Q3 		– Sell
-11,864
Closed -$244K – 2010
2022
Q2 		$244K Buy
+11,864
New +$282K ﹤0.01% 2046

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allianz Asset Management's ITOS Position: Q2 2024 in Review

Allianz Asset Management sold out of iTeos Therapeutics (ITOS) in Q2 2024, closing a stake of 20,542 shares — an estimated $280K sold.

Allianz Asset Management first reported a position in ITOS in Q2 2022 and held it in 5 quarters. The position peaked at $411K in Q1 2023. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2024.

  • Allianz Asset Management reported no remaining iTeos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Allianz Asset Management sold 20,542 iTeos Therapeutics shares in Q2 2024, an estimated $280K.
  • Allianz Asset Management first reported a position in iTeos Therapeutics in Q2 2022 and held it in 5 quarters.
  • Allianz Asset Management's iTeos Therapeutics position peaked at $411K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.